Glimepiride
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names: Glimepirid, Glimepirida, Glimepiridum, Glimepride, Amarel, Amaryl, Endial, Novo-glimepiride, PMS-glimepiride, Ratio-glimepiride, Sandoz glimepiride
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Dosing and Administration
The usual starting dose of Glimepiride as initial therapy is 1 to 2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 1 mg once daily, and should be titrated carefully.
No exact dosage relationship exists between Glimepiride and the other oral hypoglycemic agents. The maximum starting dose of Glimepiride should be no more than 2 mg.
Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Glimepiride
Return to top
Publication Resources
Most Recent Articles on Glimepiride
Review Articles on Glimepiride
Articles on Glimepiride in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Glimepiride
Return to top
Trial Resources
Ongoing Trials with Glimepiride at Clinical Trials.gov
Trial Results with Glimepiride
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Glimepiride
Cochrane Collaboration on Glimepiride
Cost Effectiveness of Glimepiride
Return to top
Media Resources
Powerpoint Slides on Glimepiride
Images of Glimepiride
Podcasts & MP3s on Glimepiride
Videos on Glimepiride
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Glimepiride
Discussion Groups on Glimepiride
Patient Handouts on Glimepiride
Blogs on Glimepiride
Glimepiride in the News
Glimepiride in the Marketplace
Return to top
International Resources
Glimepiride en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
